Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5428
Peer-review started: September 19, 2021
First decision: October 25, 2021
Revised: November 12, 2021
Accepted: April 24, 2022
Article in press: April 24, 2022
Published online: June 6, 2022
Processing time: 256 Days and 8.6 Hours
There is limited information on ipsilateral synchronous papillary renal cell carcinoma (PRCC) and clear cell renal cell carcinoma (CCRCC). Therefore, these rare tumors are often misdiagnosed preoperatively as a single tumor with intrarenal metastasis or some other diseases. Effective management and long-term overall survival might be affected because the prognosis of the two tumors differs.
We describe a case of ipsilateral synchronous PRCC and CCRCC with two histological variants in a 72-year-old man, whose mass was found incidentally, with no other chief complaints and vital signs were normal. Initial ultrasound revealed a hypoechoic lobular mass with a volume of 7.8 cm × 4.8 cm × 2.8 cm in the middle to lower pole of the left kidney. A subsequent contrast-enhanced computed tomography scan showed a single endophytic mass of 7.5 cm in diameter. The patient underwent laparoscopic left radical nephrectomy. A final diagnosis of ipsilateral synchronous PRCC and CCRCC was confirmed by pathological examination. There was no recurrence or metastasis after 25 mo follow-up.
We report a case of ipsilateral synchronous PRCC and CCRCC, and review related literature to estimate the prevalence of similar cases. The above descri
Core Tip: Ipsilateral synchronous papillary renal cell carcinoma (PRCC) and clear cell renal cell carcinoma (CCRCC) are rare, and reports on this tumor are scarce. We describe an incidentally detected case of this rare disease. Preoperative imaging examinations revealed a single mass on both ultrasound and computed tomography. Further pathological examination confirmed two types of tumors: PRCC and CCRCC. The patient underwent laparoscopic left radical nephrectomy and there was no recurrence or metastasis after 25 mo follow-up.